CA2937277C - Process for manufacturing pyrimidine sulfamide derivatives - Google Patents

Process for manufacturing pyrimidine sulfamide derivatives Download PDF

Info

Publication number: CA2937277C
Authority: CA; Canada
Prior art keywords: compound; formula; salt; aprotic organic; reaction
Prior art date: 2014-02-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

CA2937277A

Other languages

English (en)

French (fr)

Other versions

CA2937277A1 (en

Inventor

Stefan Abele

Jacques-Alexis Funel

Ivan SCHINDELHOLZ

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Idorsia Pharmaceuticals Ltd

Original Assignee

Idorsia Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-02-14

Filing date

2015-02-13

Publication date

2021-07-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50073084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2937277(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-02-13 Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd

2015-08-20 Publication of CA2937277A1 publication Critical patent/CA2937277A1/en

2021-07-06 Application granted granted Critical

2021-07-06 Publication of CA2937277C publication Critical patent/CA2937277C/en

Status Active legal-status Critical Current

2035-02-13 Anticipated expiration legal-status Critical

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Plural Heterocyclic Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Catalysts (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Compositions Of Macromolecular Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

CA2937277A 2014-02-14 2015-02-13 Process for manufacturing pyrimidine sulfamide derivatives Active CA2937277C (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP14155137.4A EP2907811A1 (en)	2014-02-14	2014-02-14	Process for manufacturing pyrimidine sulfamide derivatives
EP14155137.4		2014-02-14
PCT/EP2015/053047 WO2015121397A1 (en)	2014-02-14	2015-02-13	Process for manufacturing pyrimidine sulfamide derivatives

Publications (2)

Publication Number	Publication Date
CA2937277A1 CA2937277A1 (en)	2015-08-20
CA2937277C true CA2937277C (en)	2021-07-06

Family

ID=50073084

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2937277A Active CA2937277C (en)	2014-02-14	2015-02-13	Process for manufacturing pyrimidine sulfamide derivatives

Country Status (28)

Country	Link
US (1)	US9938244B2 (2)
EP (3)	EP2907811A1 (2)
JP (2)	JP6431922B2 (2)
KR (2)	KR102406358B1 (2)
CN (2)	CN105992762B (2)
AR (2)	AR099434A1 (2)
AU (2)	AU2015217000B2 (2)
BR (2)	BR112016018581B1 (2)
CA (1)	CA2937277C (2)
CL (2)	CL2016002008A1 (2)
CY (1)	CY1123319T1 (2)
DK (1)	DK3105220T3 (2)
EA (2)	EA032933B1 (2)
ES (2)	ES2819504T3 (2)
HK (1)	HK1243405A1 (2)
HR (1)	HRP20201450T1 (2)
HU (1)	HUE050974T2 (2)
IL (1)	IL251126A0 (2)
LT (1)	LT3105220T (2)
MX (2)	MX377801B (2)
NZ (1)	NZ724273A (2)
PL (1)	PL3105220T3 (2)
PT (1)	PT3105220T (2)
SA (1)	SA516371640B1 (2)
SG (2)	SG10201701994RA (2)
SI (1)	SI3105220T1 (2)
TW (2)	TWI666203B (2)
WO (1)	WO2015121397A1 (2)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR095727A1 (es)	2013-03-27	2015-11-04	Actelion Pharmaceuticals Ltd	Preparación de intermediarios de pirimidina
EP2907811A1 (en) *	2014-02-14	2015-08-19	Actelion Pharmaceuticals Ltd.	Process for manufacturing pyrimidine sulfamide derivatives
CN105461639B (zh) *	2015-12-10	2018-03-09	合肥久诺医药科技有限公司	一种高纯度马西替坦的精制方法
CN105461638A (zh) *	2015-12-10	2016-04-06	合肥久诺医药科技有限公司	一种马西替坦晶型及其制备方法
KR102568472B1 (ko)	2017-02-27	2023-08-18	이도르시아 파마슈티컬스 리미티드	엔도텔린 관련 질환의 치료를 위한 4-피리미딘술파미드 유도체와 활성 성분의 조합물
KR20260037123A (ko)	2017-11-30	2026-03-17	이도르시아 파마슈티컬스 리미티드	엔도텔린 관련 질병의 치료를 위한 sglt-2 저해제와의 4-피리미딘설파미드 유도체의 병용
CN109232546B (zh) *	2018-09-25	2020-09-04	中国人民解放军总医院	一种嘧啶磺酰胺类衍生物的医药用途
AU2020378025A1 (en) *	2019-11-07	2022-06-23	Crystal Pharmaceutical (Suzhou) Co., Ltd.	Crystal form of Aprocitentan, preparation method therefor and use thereof
WO2021237004A1 (en) *	2020-05-21	2021-11-25	Teva Pharmaceuticals International Gmbh	Solid state forms of aprocitentan and process for preparation thereof
CN114644595A (zh) *	2020-12-19	2022-06-21	普济生物科技（台州）有限公司	阿普昔腾坦的无定型态、其药物组合物和用途
WO2023111797A1 (en) *	2021-12-17	2023-06-22	Janssen Biotech, Inc.	Pyrimidine sulfamide derivatives and process for manufacturing them
US20250340520A1 (en)	2022-05-25	2025-11-06	Idorsia Pharmaceuticals Ltd	Crystalline forms of sodium (5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)(sulfamoyl)amide
WO2025102245A1 (zh) *	2023-11-14	2025-05-22	浙江天宇药业股份有限公司	一种双重内皮素受体拮抗剂阿普昔腾坦的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3921918A1 (de) *	1989-07-04	1991-01-17	Hoechst Ag	Verfahren zur herstellung von 2,4,6-trifluor-1,3,5-triazin
HU229403B1 (en)	2000-12-18	2013-12-30	Actelion Pharmaceuticals Ltd	Novel sulfamides and their use as endothelin receptor antagonists
TR200103716A2 (tr) *	2001-12-25	2003-07-21	Ba�Lama Al�	Zenginleştirilmiş dizel yakıt kompozisyonu
DE60224223T2 (de) *	2002-01-02	2008-12-04	Actelion Pharmaceuticals Ltd.	Neue alkylsulfonamide als endothelinantagonisten
MX2010001837A (es)	2007-08-17	2010-03-10	Actelion Pharmaceuticals Ltd	Derivados de 4-pirimidinasulfamida.
US20130310362A1 (en)	2009-02-13	2013-11-21	Bayer Pharma Aktiegesellschaft	Fused pyrimidines
WO2010144477A2 (en) *	2009-06-12	2010-12-16	Auspex Pharmaceuticals, Inc.	Sulfonylurea modulators of endothelin receptor
KR101471047B1 (ko) *	2012-11-21	2014-12-08	주식회사 메디켐코리아	고순도 보센탄의 개선된 제조방법
CN103012279B (zh) *	2012-11-27	2015-01-28	浙江工业大学	一种4,5,6-三氟嘧啶化合物的制备方法
AR095727A1 (es)	2013-03-27	2015-11-04	Actelion Pharmaceuticals Ltd	Preparación de intermediarios de pirimidina
CN103724281A (zh) *	2013-12-03	2014-04-16	镇江圣安医药有限公司	N-[5-（4-溴苯基）-6-[2-[（5-溴-2-嘧啶基）氧基]乙氧基]-4-嘧啶基]-n′-丙基磺酰胺的新型衍生物及其应用
EP2907811A1 (en) *	2014-02-14	2015-08-19	Actelion Pharmaceuticals Ltd.	Process for manufacturing pyrimidine sulfamide derivatives

2014
- 2014-02-14 EP EP14155137.4A patent/EP2907811A1/en not_active Withdrawn
2015
- 2015-02-13 PT PT157061854T patent/PT3105220T/pt unknown
- 2015-02-13 AU AU2015217000A patent/AU2015217000B2/en active Active
- 2015-02-13 KR KR1020177006399A patent/KR102406358B1/ko not_active Expired - Fee Related
- 2015-02-13 EP EP15706185.4A patent/EP3105220B1/en active Active
- 2015-02-13 PL PL15706185T patent/PL3105220T3/pl unknown
- 2015-02-13 TW TW106114126A patent/TWI666203B/zh not_active IP Right Cessation
- 2015-02-13 EA EA201691618A patent/EA032933B1/ru not_active IP Right Cessation
- 2015-02-13 DK DK15706185.4T patent/DK3105220T3/da active
- 2015-02-13 BR BR112016018581-1A patent/BR112016018581B1/pt active IP Right Grant
- 2015-02-13 LT LTEP15706185.4T patent/LT3105220T/lt unknown
- 2015-02-13 MX MX2017003134A patent/MX377801B/es unknown
- 2015-02-13 CA CA2937277A patent/CA2937277C/en active Active
- 2015-02-13 MX MX2016010486A patent/MX368014B/es active IP Right Grant
- 2015-02-13 SI SI201531349T patent/SI3105220T1/sl unknown
- 2015-02-13 ES ES15706185T patent/ES2819504T3/es active Active
- 2015-02-13 KR KR1020167025089A patent/KR102261695B1/ko active Active
- 2015-02-13 HU HUE15706185A patent/HUE050974T2/hu unknown
- 2015-02-13 CN CN201580008410.3A patent/CN105992762B/zh active Active
- 2015-02-13 SG SG10201701994RA patent/SG10201701994RA/en unknown
- 2015-02-13 CN CN201710130956.7A patent/CN107162988B/zh active Active
- 2015-02-13 AR ARP150100449A patent/AR099434A1/es active IP Right Grant
- 2015-02-13 BR BR122017005939-4A patent/BR122017005939B1/pt active IP Right Grant
- 2015-02-13 NZ NZ724273A patent/NZ724273A/en unknown
- 2015-02-13 EP EP17159638.0A patent/EP3214082B1/en active Active
- 2015-02-13 SG SG11201606667VA patent/SG11201606667VA/en unknown
- 2015-02-13 WO PCT/EP2015/053047 patent/WO2015121397A1/en not_active Ceased
- 2015-02-13 EA EA201790343A patent/EA032460B1/ru not_active IP Right Cessation
- 2015-02-13 ES ES17159638T patent/ES2906458T3/es active Active
- 2015-02-13 US US15/118,046 patent/US9938244B2/en active Active
- 2015-02-13 HR HRP20201450TT patent/HRP20201450T1/hr unknown
- 2015-02-13 JP JP2016551796A patent/JP6431922B2/ja active Active
- 2015-02-13 TW TW104105167A patent/TWI663155B/zh active
2016
- 2016-08-09 SA SA516371640A patent/SA516371640B1/ar unknown
- 2016-08-10 CL CL2016002008A patent/CL2016002008A1/es unknown
2017
- 2017-03-03 AR ARP170100539A patent/AR107801A2/es unknown
- 2017-03-03 CL CL2017000505A patent/CL2017000505A1/es unknown
- 2017-03-09 JP JP2017044868A patent/JP6421209B2/ja active Active
- 2017-03-13 IL IL251126A patent/IL251126A0/en active IP Right Grant
- 2017-04-12 AU AU2017202446A patent/AU2017202446B2/en not_active Ceased
2018
- 2018-02-27 HK HK18102771.1A patent/HK1243405A1/en unknown
2020
- 2020-09-04 CY CY20201100833T patent/CY1123319T1/el unknown

Also Published As

Publication number	Publication date
AU2015217000A1 (en)	2016-09-29
CY1123319T1 (el)	2021-12-31
MX377801B (es)	2025-03-11
HUE050974T2 (hu)	2021-01-28
SG11201606667VA (en)	2016-09-29
EP3214082B1 (en)	2021-11-10
CA2937277A1 (en)	2015-08-20
BR122017005939B1 (pt)	2022-12-20
NZ724273A (en)	2020-06-26
BR112016018581B1 (pt)	2022-11-16
BR112016018581A2 (pt)	2017-08-08
CN107162988B (zh)	2020-08-21
HRP20201450T1 (hr)	2020-12-25
WO2015121397A1 (en)	2015-08-20
AU2017202446B2 (en)	2019-03-28
CN105992762B (zh)	2019-04-16
LT3105220T (lt)	2020-10-12
SG10201701994RA (en)	2017-05-30
CN107162988A (zh)	2017-09-15
JP2017125055A (ja)	2017-07-20
SA516371640B1 (ar)	2019-09-08
US20160368882A1 (en)	2016-12-22
EA032933B1 (ru)	2019-08-30
AU2017202446A1 (en)	2017-05-04
MX2016010486A (es)	2016-10-31
MX368014B (es)	2019-09-13
JP6421209B2 (ja)	2018-11-07
KR20170029656A (ko)	2017-03-15
AU2015217000B2 (en)	2019-02-14
KR102261695B1 (ko)	2021-06-07
TW201613877A (en)	2016-04-16
BR122017005939A2 (pt)	2019-09-10
TW201730157A (zh)	2017-09-01
EA201790343A1 (ru)	2017-06-30
AR099434A1 (es)	2016-07-20
TWI663155B (zh)	2019-06-21
BR112016018581A8 (pt)	2021-06-22
EP3105220B1 (en)	2020-07-01
US9938244B2 (en)	2018-04-10
KR20160122213A (ko)	2016-10-21
PL3105220T3 (pl)	2020-12-28
DK3105220T3 (da)	2020-09-07
EP3214082A1 (en)	2017-09-06
SI3105220T1 (sl)	2020-10-30
TWI666203B (zh)	2019-07-21
ES2906458T3 (es)	2022-04-18
CL2016002008A1 (es)	2017-02-03
EP2907811A1 (en)	2015-08-19
IL251126A0 (en)	2017-04-30
NZ729685A (en)	2020-11-27
JP2017505801A (ja)	2017-02-23
CN105992762A (zh)	2016-10-05
EA032460B1 (ru)	2019-05-31
EA201691618A1 (ru)	2017-01-30
HK1243405A1 (en)	2018-07-13
AR107801A2 (es)	2018-06-06
CL2017000505A1 (es)	2017-11-24
JP6431922B2 (ja)	2018-11-28
KR102406358B1 (ko)	2022-06-07
ES2819504T3 (es)	2021-04-16
EP3105220A1 (en)	2016-12-21
PT3105220T (pt)	2020-09-23

Legal Events

Date	Code	Title	Description
2020-02-21	EEER	Examination request	Effective date: 20200213
2025-02-03	MPN	Maintenance fee for patent paid	Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD Year of fee payment: 10
2025-02-03	U00	Fee paid	Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250203
2025-02-03	U11	Full renewal or maintenance fee paid	Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250203 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250203
2025-12-03	MPN	Maintenance fee for patent paid	Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD Year of fee payment: 11
2025-12-03	U00	Fee paid	Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251203
2025-12-03	U11	Full renewal or maintenance fee paid	Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251203

Publication	Publication Date	Title
CA2937277C (en)	2021-07-06	Process for manufacturing pyrimidine sulfamide derivatives
CA2900911C (en)	2020-10-13	Preparation of pyrimidine intermediates useful for the manufacture of macitentan
NZ729685B2 (en)	2021-03-02	Process for manufacturing pyrimidine sulfamide derivatives
DK3019479T3 (en)	2017-07-17	PROCEDURE FOR THE PREPARATION OF A PYRIMIDINE INTERMEDIATE